Torthaí cuardaigh

Topaicí molta laistigh de do chuardach.
Beachtaigh na torthaí
  1. 1
    Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease de réir John K MacDonald, Tran M Nguyen, Reena Khanna, Antje Timmer

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials

    Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomiz... de réir Thrasyvoulos Tzellos, Athanassios Kyrgidis, Christos C. Zouboulis

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial

    Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial de réir Atsuyuki Igarashi, Takeshi Kato, Mai Kato, Michael Song, Hidemi Nakagawa

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Treatment of severe refractory adult atopic dermatitis with ustekinumab

    Treatment of severe refractory adult atopic dermatitis with ustekinumab de réir Rafael Jiménez Puya, María Ángeles Álvarez‐López, Antonio Vélez García‐Nieto, Enrique Casas de la Asunción, J.C. Moreno

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

    Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents de réir Wolfgang Weger

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

    Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic In... de réir Richard B. Warren, Catherine Smith, Zenas Z N Yiu, Darren M. Ashcroft, Juliet N. Barker, A. David Burden, Mark Lunt, Kathleen McElhone, Anthony D. Ormerod, Caroline Owen, Nick J. Reynolds, C.E.M. Griffiths

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Demographics and disease characteristics of patients with psoriasis enrolled in the <scp>B</scp> ritish <scp>A</scp> ssociation of <scp>D</scp> ermatologists <scp>B</scp> iologic <scp>I</scp> nterventions <scp>R</scp> egister

    Demographics and disease characteristics of patients with psoriasis enrolled in the <scp>B</scp> ritish <scp>A</scp> ssociation of <scp>D</scp> ermatologists <scp>B</scp> iologic <... de réir Ireny Iskandar, Darren M. Ashcroft, Richard B. Warren, Zenas Z N Yiu, Kathleen McElhone, Mark Lunt, Juliet N. Barker, A. David Burden, Anthony D. Ormerod, Nick J. Reynolds, Catherine Smith, C.E.M. Griffiths

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial

    Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐C... de réir Arthur Kavanaugh, L. Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Shu Li, Yuhua Wang, Alan M. Mendelsohn, Michael Song, Yaowei Zhu, Proton Rahman, Iain B. McInnes

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

    Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study de réir Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F. Eichenfield, Peter H. Hoeger, Alan Menter, Amy S. Paller, Alain Taı̈eb, Sandra Philipp, Philippe Szapary, B. Randazzo

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

    Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents de réir Pauline Wils, Yoram Bouhnik, Pierre Michetti, Bernard Flourié, Hédia Brixi, Anne Bourrier, Matthieu Allez, Bernard Duclos, Jean–Charles Grimaud, Anthony Buisson, Aurélien Amiot, Mathurin Fuméry, Xavier Roblin, Laurent Peyrin–Biroulet, Jérôme Filippi, Guillaume Bouguen, Véred Abitbol, Benoît Coffin, Marion Simon, David Laharie, Benjamin Pariente

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis

    Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis de réir Alexander Nast, Anja Jacobs, Stefanie Rosumeck, Ricardo Niklas Werner

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

    Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies de réir Kristian Reich, Richard Langley, Mark Lebwohl, Philippe Szapary, Cynthia Guzzo, Newman Yeilding, S. Li, M-C. Hsu, C.E.M. Griffiths

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial de réir Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

    Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience de réir Uri Kopylov, Waqqas Afif, A Cohen, Alain Bitton, Gary Wild, Talat Bessissow, Jonathan Wyse, Talal Al-Taweel, Andrew Szilagyi, Ernest G. Seidman

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

    Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of... de réir Richard Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Y. Wasfi, Daphne Chan, Ming-Chun Hsu, Yin You, Yves Poulin, Neil J. Korman, Jörg C. Prinz, Kristian Reich

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications

    The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications de réir Beatrice Marinoni, Angela Ceribelli, Marco Massarotti, Carlo Selmi

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    The use of ustekinumab in a patient with severe psoriasis and positive HBV serology

    The use of ustekinumab in a patient with severe psoriasis and positive HBV serology de réir Raquel Bissacotti Steglich, Luana Pizarro Meneghello, André Vicente Esteves de Carvalho, Hugo Cheinquer, Fernanda Melo Müller, Flávia Pereira Reginatto

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis

    Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis de réir L. Savage, Miriam Wittmann, Dennis McGonagle, Philip Helliwell

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy

    Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy de réir Elizabeth A. Brezinski, April W. Armstrong

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn’s Disease on Maintenance Treatment with Biologics

    Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn’s Disease on Maintenance Treatment with Biologics de réir Fabiana Castiglione, Anna Testa, Matilde Rea, Giovanni Domenico De Palma, M. Diaferia, Dario Musto, F Sasso, Nicola Caporaso, Antonio Rispo

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: